🔗 Share this article

Ex-government leader Rishi Sunak has intensified his call for a targeted screening programme for prostate cancer.

During a recently conducted interview, he stated being "convinced of the immediate need" of implementing such a initiative that would be affordable, achievable and "protect innumerable lives".

His remarks emerge as the British Screening Authority reviews its decision from five years ago not to recommend regular testing.

Media reports propose the authority may uphold its current stance.

Athlete Adds Support to Campaign

Olympic cycling champion Sir Chris Hoy, who has advanced prostate gland cancer, advocates for younger men to be tested.

He suggests lowering the age threshold for accessing a prostate-specific antigen blood screening.

Currently, it is not routinely offered to men without symptoms who are below fifty.

The prostate-specific antigen screening is controversial though. Measurements can elevate for causes apart from cancer, such as infections, leading to false positives.

Skeptics maintain this can result in unwarranted procedures and adverse effects.

Focused Testing Proposal

The recommended screening programme would concentrate on males between 45 and 69 with a hereditary background of prostate gland cancer and men of African descent, who face twice the likelihood.

This population comprises around over a million males in the United Kingdom.

Charity estimates suggest the initiative would require £25m annually - or about £18 per person per patient - similar to intestinal and breast examination.

The estimate involves 20% of eligible men would be invited each year, with a 72% uptake rate.

Medical testing (scans and biopsies) would need to rise by 23%, with only a reasonable growth in healthcare personnel, according to the report.

Medical Community Response

Some healthcare professionals are doubtful about the effectiveness of screening.

They argue there is still a chance that men will be medically managed for the condition when it is not strictly necessary and will then have to live with side effects such as urinary problems and sexual performance issues.

One leading urological expert remarked that "The issue is we can often identify disease that doesn't need to be treated and we end up causing harm...and my worry at the moment is that negative to positive balance isn't quite right."

Patient Perspectives

Individual experiences are also affecting the conversation.

A particular example features a sixty-six year old who, after requesting a prostate screening, was diagnosed with the condition at the time of fifty-nine and was informed it had spread to his pelvis.

He has since experienced chemotherapy, radiation treatment and endocrine treatment but cannot be cured.

The patient advocates screening for those who are at higher risk.

"This is essential to me because of my children – they are 38 and 40 – I want them tested as quickly. If I had been tested at fifty I am sure I would not be in the circumstances I am now," he commented.

Next Steps

The Screening Advisory Body will have to evaluate the information and arguments.

While the new report says the ramifications for workforce and capacity of a examination system would be feasible, some critics have maintained that it would redirect scanning capacity away from patients being treated for different health issues.

The ongoing discussion highlights the multifaceted trade-off between prompt identification and possible unnecessary management in prostate gland cancer treatment.